Myocardial creatine levels do not influence response to acute oxidative stress in isolated perfused heart

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Aksentijevic, Dunja ^a,b   Zervou, Sevasti ^a   Faller, Kiterie M E ^a   McAndrew, Debra J ^a   Schneider, Jurgen E ^a   Neubauer, Stefan ^a   Lygate, Craig A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CATALASE; CREATINE; CREATINE KINASE; CREATINE TRANSPORTER; DOXORUBICIN; HYDROGEN PEROXIDE; PROTEIN KINASE C DELTA; RAZOXANE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; HEART MUSCLE CONTRACTILITY; ISOLATED HEART; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; IN VITRO STUDY; METABOLISM; PILOT STUDY;

ANIMALS; APOPTOSIS; BIOMARKERS; CREATINE; IN VITRO TECHNIQUES; MICE; MICE, INBRED C57BL; MYOCARDIUM; OXIDATIVE STRESS; PILOT PROJECTS; REACTIVE OXYGEN SPECIES;

EID: 84907486815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109021     Document Type: Article

References (50)

1. Neubauer S (2007) The failing heart-an engine out of fuel. New Eng J Med 356: 1140-1151.
2. Berneburg M, Gremmel T, Kurten V., Schroeder P, Hertel I, et al. (2005) Creatine supplementation normalizes mutagenesis of mitochondrial DNA as well as functional consequences. J Invest Dermatol 125: 213-220.
3. Fimognari C, Sestili P, Lenzi M., Cantelli-Forti G, Hrelia P. (2009) Protective effect of creatine against RNA damage. Mutat Res 670: 59-67.
4. Guidi C, Potenza L, Sestili P., Martinelli C, Guescini M, et al. (2008) Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. Biochim Biophys Acta 1780: 16-26.
5. Lawler JM, Barnes WS, Wu G, Song W., Demaree S. (2002) Direct antioxidant properties of creatine. Biochem Biophys Res Commun 290: 47-52.
6. Sestili P, Martinelli C, Bravi G., Piccoli G, Curci R, et al. (2006) Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med 40: 837-849.
7. Young JF, Larsen LB, Malmendal A, Nielsen N.C., Straadt IK, et al. (2010) Creatine-induced activation of antioxidative defence in myotube cultures revealed by explorative NMR-based metabonomics and proteomics. J Int Soc Sports Nutr 7: 9.
8. Alcaide P, Merinero B, Ruiz-Sala P, Richard E., Navarrete R, et al. (2011) Defining the pathogenicity of creatine deficiency syndrome. Hum Mutat 32: 282-291.
9. Bender A, Beckers J, Schneider I., Holter SM, Haack T, et al. (2008) Creatine improves health and survival of mice. Neurobiol Aging 29: 1404-1411.
10. Lygate CA, Bohl S, ten Hove M, Faller KM, Ostrowski P.J., et al. (2012) Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. Cardiovasc Res 96: 466-475.
11. Schroder E, Eaton P. (2008) Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: issues and considerations. Curr Opin Pharmacol 8: 153-159.
12. Avner BS, Hinken AC, Yuan C, Solaro R.J. (2010) H2O2 alters rat cardiac sarcomere function and protein phosphorylation through redox signaling. Am J Physiol Heart Circ Physiol 299: H723-730.
13. Canton M, Neverova I, Menabo R., Van Eyk J, Di Lisa F (2004) Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. Am J Physiol Heart Circ Physiol 286: H870-877.
14. Janero DR, Hreniuk D, Sharif H.M. (1991) Hydrogen peroxide-induced oxidative stress to the mammalian heart-muscle cell (cardiomyocyte): lethal peroxidative membrane injury. J Cell Physiol 149: 347-364.
15. Chatham JC, Gilbert HF, Radda G.K. (1989) The metabolic consequences of hydroperoxide perfusion on the isolated rat heart. Eur J Biochem 184: 657-662.
16. Maslov MY, Chacko VP, Hirsch G.A., Akki A., Leppo MK, et al. (2010) Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 299: H332-337.
17. Tokarska-Schlattner M, Wallimann T, Schlattner U. (2006) Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol 329: 657-668.
18. Gratia S, Kay L, Potenza L., Seffouh A, Novel-Chate V, et al. (2012) Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res 95: 290-299.
19. Snow RJ, Murphy R.M. (2001) Creatine and the creatine transporter: a review. Mol Cell Biochem 224: 169-181.
20. Boehm E, Chan S, Monfared M., Wallimann T, Clarke K, et al. (2003) Creatine transporter activity and content in the rat heart supplemented by and depleted of creatine. Am J Physiol Endocrinol Metab 284: E399-406.
21. Wallis J, Lygate CA, Fischer A, ten Hove M, Schneider JE, et al. (2005) Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure: insights from creatine transporter-overexpressing transgenic mice. Circulation 112: 3131-3139.
22. Schmidt A, Marescau B, Boehm E.A., Renema WK, Peco R, et al. (2004) Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum Mol Genet 13: 905-921.
23. ten Hove M, Lygate CA, Fischer A, Schneider J.E., Sang AE, et al. (2005) Reduced inotropic reserve and increased susceptibility to cardiac ischemia/ reperfusion injury in phosphocreatine-deficient guanidinoacetate-N-methyl-transferase-knockout mice. Circulation 111: 2477-2485.
24. Schneider JE, Tyler DJ, ten Hove M, Sang AE, Cassidy P.J., et al. (2004) In vivo cardiac 1H-MRS in the mouse. Magn Reson Med 52: 1029-1035.
25. Ogino H, Smolenski RT, Zych M, Seymour A.M., Yacoub M.H. (1996) Influence of preconditioning on rat heart subjected to prolonged cardioplegic arrest. Ann Thorac Surg 62: 469-474.
26. Pelikan PC, Weisfeldt ML, Jacobus W.E., Miceli MV, Bulkley BH, et al. (1986) Acute doxorubicin cardiotoxicity: functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. J Cardiovasc Pharmacol 8: 1058-1066.
27. Tokarska-Schlattner M, Wallimann T, Schlattner U. (2002) Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol Pharmacol 61: 516-523.
28. Muller M, Moser R, Cheneval D., Carafoli E. (1985) Cardiolipin is the membrane receptor for mitochondrial creatine phosphokinase. J Biol Chem 260: 3839-3843.
29. Lygate CA, Hunyor I, Medway D., de Bono JP, Dawson D, et al. (2009) Cardiac phenotype of mitochondrial creatine kinase knockout mice is modified on a pure C57BL/6 genetic background. J Mol Cell Cardiol 46: 93-99.
30. ten Hove M, Makinen K, Sebag-Montefiore L, Hunyor I., Fischer A, et al. (2008) Creatine uptake in mouse hearts with genetically altered creatine levels. J Mol Cell Cardiol 45: 453-459.
31. Divald A, Kivity S, Wang P., Hochhauser E, Roberts B, et al. (2010) Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 106: 1829-1838.
32. Wang P, Powell S.R. (2010) Decreased sensitivity associated with an altered formulation of a commercially available kit for detection of protein carbonyls. Free Radic Biol Med 49: 119-121.
33. Lygate CA, Bohl S, ten Hove M, Faller KM, Ostrowski P.J., et al. (2012) Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction. Cardiovasc Res 96: 466-475.
34. Tokarska-Schlattner M, Zaugg M, Zuppinger C., Wallimann T, Schlattner U. (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41: 389-405.
35. Zucchi R, Poddighe R, Limbruno U., Mariani M, Ronca-Testoni S, et al. (1989) Protection of isolated rat heart from oxidative stress by exogenous creatine phosphate. J Mol Cell Cardiol 21: 67-73.
36. Anyukhovsky EP, Javadov SA, Preobrazhensky A.N., Beloshapko GG, Rosensh-traukh LV, et al. (1986) Effect of phosphocreatine and related compounds on the phospholipid metabolism of ischemic heart. Biochem Med Metab Biol 35: 327-334.
37. Tokarska-Schlattner M, Epand RF, Meiler F, Zandomeneghi G., Neumann D, et al. (2012) Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects. PLOS ONE 7: e43178.
38. Lygate CA, Aksentijevic D, Dawson D., ten Hove M, Phillips D, et al. (2013) Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ Res 112: 945-955.
39. Zugno AI, Stefanello FM, Scherer E.B., Mattos C., Pederzolli CD, et al. (2008) Guanidinoacetate decreases antioxidant defenses and total protein sulfhydryl content in striatum of rats. Neurochem Res 33: 1804-1810.
40. NICE (2010) Management of chronic heart failure in adults in primary and secondary care http://www.nice.org.uk/guidance/cg108.
41. Cardinale D, Colombo A, Lamantia G., Colombo N, Civelli M, et al. (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55: 213-220.
42. Hausenloy DJ, Baxter G, Bell R., Botker HE, Davidson SM, et al. (2010) Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol 105: 677-686.
43. Ali SS, Xiong C, Lucero J., Behrens MM, Dugan LL, et al. (2006) Gender differences in free radical homeostasis during aging: shorter-lived female C57BL6 mice have increased oxidative stress. Aging Cell 5: 565-574.
44. Deschamps AM, Murphy E, Sun J. (2010) Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovas Med 20: 73-78.
45. Sun LY, Wang N, Ban T., Sun YH, Han Y, et al. (2014) MicroRNA-23a mediates mitochondrial compromise in estrogen deficiency-induced concentric remodeling via targeting PGC-1alpha. J Mol Cell Cardiol 75C: 1-11.
46. Tokarska-Schlattner M, Wallimann T, Schlattner U. (2006) Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C R Biol 329: 657-668.
47. Streijger F, Pluk H, Oerlemans F., Beckers G, Bianco AC, et al. (2009) Mice lacking brain-type creatine kinase activity show defective thermoregulation. Physiol Behav 97: 76-86.
48. Darrabie MD, Arciniegas AJL, Mantilla JG, Mishra R, Vera M.P., et al. (2012) Exposing cardiomyocytes to subclinical concentrations of doxorubicin rapidly reduces their creatine transport. Am J Physiol Heart Circ Physiol 303: H539-H548.
49. Gupta A, Rohlfsen C, Leppo M.K., Chacko VP, Wang Y, et al. (2013) Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity. PLOS ONE 8: e74675.
50. Santos RV, Batista ML, Jr., Caperuto EC, Costa Rosa LF (2007) Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after Doxorubicin treatment in rats. Clin Exp Pharmacol Physiol 34: 1294-1299.